Integral Diagnostics Ltd (ASX: IDX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Integral Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $736.59 million
P/E Ratio 30.30
Dividend Yield 3.43%
Shares Outstanding 231.63 million
Earnings per share 0.105
Dividend per share 0.11
Year To Date Return -33.91%
Earnings Yield 3.30%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Integral Diagnostics Ltd (ASX: IDX)
Latest News

private health insurance diagram.
Healthcare Shares

Goldman names 2 ASX healthcare shares to buy

Here are two healthcare shares that are rated highly...

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Goldman Sachs names 3 ASX healthcare shares to buy

Here are three healthcare shares that Goldman rates highly...

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Small Cap Shares

7 small-cap ASX shares that have been oversold: Wilsons

This bunch of smaller companies haven't essentially changed their performance or outlook, yet have been punished by investors.

Read more »

Rede arrow on a stock market chart going down.
Share Fallers

Why ASX, Coronado, Graincorp, and Integral Diagnostics shares are dropping today

These ASX shares are missing out on the market rally today....

Read more »

A man looks surprised as a woman whispers in his ear.
Broker Notes

2 ASX shares to buy now at bargain prices that you’ve forgotten about

There are many cheap stocks currently out there to consider. Here's a pair you might not have on your radar.

Read more »

sad, unhappy technology users, technology share price drop, fall, decrease, slide
52-Week Lows

Is opportunity knocking? 2 ASX All Ordinaries shares hitting 52-week lows

Catch a falling knife? Or opportunity knocking?

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Earnings Results

Integral Diagnostics (ASX:IDX) share price on ice after trio of big announcements

Here's the latest on the ASX diagnostics company amid its half-year results.

Read more »

two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
Ask a Fund Manager

2 ASX shares to buy for dirt cheap right now: expert

Ask A Fund Manager: Forager Funds Management's Gaston Amoros names a pair of stocks that the market is unfairly punishing.

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
01 Mar 2022 $0.0400 100.00% Interim 04 Apr 2022
02 Sep 2021 $0.0700 100.00% Final 06 Oct 2021
01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
31 Aug 2017 $0.0400 100.00% Final 04 Oct 2017
28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

IDX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Integral Diagnostics Ltd

Integral Diagnostics Ltd is an Australian healthcare services company. The group operates in a single business. It provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients.

IDX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
18 Aug 2022 $3.18 $-0.03 -0.93% 201,713 $3.22 $3.22 $3.12
17 Aug 2022 $3.21 $0.04 1.26% 90,246 $3.17 $3.24 $3.15
16 Aug 2022 $3.17 $0.00 0.00% 261,889 $3.18 $3.22 $3.13
15 Aug 2022 $3.17 $0.00 0.00% 230,560 $3.15 $3.22 $3.15
12 Aug 2022 $3.17 $-0.03 -0.94% 472,524 $3.15 $3.21 $3.12
11 Aug 2022 $3.20 $0.09 2.89% 653,348 $3.20 $3.24 $3.16
10 Aug 2022 $3.11 $-0.11 -3.42% 354,233 $3.24 $3.24 $3.11
09 Aug 2022 $3.22 $-0.05 -1.53% 232,926 $3.34 $3.34 $3.21
08 Aug 2022 $3.27 $-0.09 -2.68% 883,430 $3.35 $3.39 $3.27
05 Aug 2022 $3.36 $0.10 3.07% 634,428 $3.27 $3.37 $3.26
04 Aug 2022 $3.26 $0.09 2.84% 722,470 $3.20 $3.29 $3.19
03 Aug 2022 $3.17 $-0.15 -4.52% 752,935 $3.32 $3.32 $3.17
02 Aug 2022 $3.32 $0.10 3.11% 854,806 $3.25 $3.33 $3.22
01 Aug 2022 $3.22 $0.13 4.21% 580,264 $3.14 $3.24 $3.14
29 Jul 2022 $3.09 $0.06 1.98% 798,283 $2.90 $3.09 $2.90
28 Jul 2022 $3.03 $0.19 6.69% 851,428 $2.93 $3.06 $2.84
27 Jul 2022 $2.84 $0.08 2.90% 2,366,722 $2.42 $2.89 $2.38
26 Jul 2022 $2.76 $-0.09 -3.16% 1,002,363 $2.85 $2.85 $2.71
25 Jul 2022 $2.85 $-0.09 -3.06% 390,398 $2.93 $2.94 $2.84
22 Jul 2022 $2.94 $0.05 1.73% 1,131,343 $2.90 $2.96 $2.88
21 Jul 2022 $2.89 $0.00 0.00% 1,446,497 $2.88 $2.91 $2.82
20 Jul 2022 $2.89 $-0.05 -1.70% 666,759 $2.95 $3.00 $2.87

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
04 Apr 2022 John Atkin Issued 1 $6,449
Dividend Reinvestment Plan (DRP).
22 Mar 2022 John Atkin Issued 20 $71,576
Rights issue.
22 Mar 2022 Ian Kadish Issued 87 $300,920
Rights issue.
28 Feb 2022 Jacqueline Milne Buy 19 $69,650
On-market trade.
22 Feb 2022 Helen Kurincic Issued 63 $218,422
Rights issue.
08 Nov 2021 Ian Kadish Issued 157 $775,839
Issue of securities. 777,559 - Performance Rights
06 Oct 2021 John Atkin Issued 2 $11,124
Dividend Reinvestment Plan (DRP).
06 Oct 2021 Rupert Harrington Issued 3 $14,797
Dividend Reinvestment Plan (DRP).
06 Oct 2021 Rupert Harrington Issued 2 $10,228
Dividend Reinvestment Plan (DRP).
31 Aug 2021 Ian Kadish Buy 362 $1,675,142
Conversion of securities.
31 Aug 2021 Ian Kadish Exercise 362 $1,675,142
Conversion of securities. 620,188 - Rights
As per announcement on 01/09/2021

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Andrew James Fay Non-Executive Director Jul 2022
Mr Fay has over 30 years of experience in the financial services industry, having knowledge of investment and funds management. His executive experience included Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited and has provided corporate strategic advice across diverse industries. Mr Fay has experience as a company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, strategy, executive remuneration frameworks, investment and corporate governance. He is currently a non-executive director of National Cardiac Pty Ltd and formerly a nonexecutive director of numerous entities including Pendal Group Ltd (ASX:PDL), Spark Infrastructure RE Limited (ASX:SKI), Cromwell Property Group (ASX:CMW), JO Hambro Capital Management Holdings Ltd, South Australian and Victorian Power Networks, Gateway Lifestyle Group and Chair of Deutsche Managed Investments Ltd. He is also a Member of the Risk & Compliance Committee, Member of the People, Culture Committee and Chair the Mergers and Acquisitions Working Group.
Dr Jacqueline Milne Executive Director Nov 2019
Dr Milne began her medical career as a practicing radiographer at South Coast Radiology prior to commencing her medical degree and radiology qualifications. The multidisciplinary experience Dr Milne brings as both a radiographer and radiologist to the Board is invaluable. Dr Milne's specialty interests include women's imaging, medical training and general procedural work. Dr Milne is also an active member of the IDX Queensland radiologist group being a member of the Queensland Clinical Leadership Committee.
Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
Ms Murphy has over 30 years experience in strategic, financial and operational leadership in both industry and professional advisory after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career she specialised in operational and financial restructuring with a particular emphasis on merger and acquisition integration across a range of significant public and private companies. Ms Murphy is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX Listed companies. She is currently a Non-Executive Director of ASX listed Altium Limited (ASX:ALU), Bega Limited (ASX:BGA) and Elders Limited (ASX:ELD).
Ms Helen Kurincic Non-Executive ChairmanNon-Executive Director Dec 2014
Ms Kurincic has Executive and Board-level experience across the healthcare industry. Previously, Ms Kurincic was the Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first and largest radiation oncology and cardiology business across Australia. Prior to that, Ms Kurincic held various Executive and Non-Executive healthcare sector roles including Non-Executive Director of DCA Group Ltd (diagnostic imaging services in Australia and the United Kingdom), Non-Executive Director of AMP Capital Investors Domain Principal Group, CEO of Benetas and NonExecutive Director of Melbourne Health and Orygen Research Centre. Ms Kurincic has also been actively involved in healthcare government policy reform including appointments by health ministers as Chair of the Professional Programs and Services Committee for the Fourth Community Pharmacy Agreement and Member of the Minister's Implementation Taskforce and Minister's Reference Group for the Long Term Reform of Aged Care. She is currently the Independent Non-Executive Chair of McMillian Shakespeare Limited (ASX:MMS), a Non-Executive Director of Estia Health Limited (ASX:EHE), HBF Health Limited, and the Victorian Clinical Genetics Service. She is also a senior advisor in the healthcare sector.
Mr John Atkin Non-Executive Director Oct 2015
Mr Atkins is an experienced company director and in 2018, Mr Atkins was appointed Chair of the Australian Institute of Company Directors. Mr Atkins was Chief Executive Officer and Managing Director of The Trust Company Limited from 2009 to 2013 prior to its successful merger with Perpetual Limited. Prior to joining the Trust Company, Mr Atkins was the managing partner and Chief Executive Officer of leading Australasian law firm Blake Dawson (now Ashurst). Before this, Mr Atkins was a senior mergers and acquisitions partner of Mallesons Stephen Jaques (now King & Wood Mallesons). He is currently a Non-Executive Director of IPH Limited (ASX:IPH). Mr Atkins is also a director of a number of unlisted entities including Qantas Superannuation Limited, trustee of the Qantas Superannuation Fund and Outward Bound International Inc.
Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. He had several roles overseas including with McKinsey and Company, CSC Healthcare in New York City, and Netcare, a major hospital group in South Africa and the United Kingdom, where Dr Kadish was an Executive Director from 1997 to 2006. Mr Kadish was instrumental in growing the group from five hospitals with a market capitalisation of $60 million, to 119 hospitals and a market capitalisation of $3 billion. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group (previously ASXlisted hospital group) and CEO of Laverty Pathology. Mr Kadish is also a Non-Executive Director of Teaminvest Private Group Limited (ASX:TIP).
Dr Nazar Bokani Executive Director Apr 2021
Besides general radiological and interventional work Dr Bokani covers cross-sectional CT & MRI work, Cardiac CT, Ultrasound and symptomatic breast sessions both diagnostic and interventional. Dr Bokani is also an active member of the IDX Western Australian radiologist group being a member of the Western Australian Clinical Leadership Committee.
Ms Kirsty Lally Company Secretary Jul 2019
Anne Lockwood Chief Financial and Commercial Officer
Paul McCrow Chief Operating Officer
Kirsty Lally Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 35,091,908 17.67%
HSBC Custody Nominees (Australia) Limited 24,201,530 12.18%
Citicorp Nominees Pty Limited 19,851,055 9.99%
National Nominees Limited 11,501,438 5.79%
BNP Paribas Noms Pty Ltd <Drp> 7,248,733 3.65%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp> 3,831,101 1.93%
Peter J Ansley + St Leger M Reeves + Stephen Eichsteadt + Thomas Q St Leger 3,747,786 1.89%
Reeves <Magnolia A/C> 3,108,210 1.56%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 3,001,725 1.51%
New Imaging Pty Ltd <New Imaging A/C> 2,467,230 1.24%
Lethean Holdings Pty Ltd <Howitt No 8 A/C> 2,357,230 1.19%
Firbar Pty Ltd <The Howitt No 4 A/C> 2,293,174 1.15%
Wyndham Salter Pty Ltd <The Howitt No 10 A/C> 2,128,000 1.07%
Mr Vincent Michael O'Sullivan <O'Sullivan A/C> 2,085,907 1.05%
Mittal Holdings Pty Ltd <Howitt No 12 A/C> 2,080,133 1.05%
Lockwood Ridge Pty Ltd <The Aj French Family A/C> 2,074,375 1.04%
Nw3 Pty Ltd <The Howitt No 7 A/C> 1,806,118 0.91%
HSBC Custody Nominees (Australia) Limited <Nt - Comnwlth Super Corp A/C> 1,654,326 0.83%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 1,617,402 0.81%
Willowbay Rise Pty Ltd <Howitt No 5 A/C> 1,484,961 0.75%